相关实验视频
Updated: Jul 29, 2025

07:09
The Sciatic Nerve Cuffing Model of Neuropathic Pain in Mice
Published on: July 16, 2014
48.3K
胰岛素类生长因子-1 (IGF-1) 相关药物在疼痛管理中的作用
Seokhyun Jin1, Jianguo Cheng1,2,3
1Department of Pain Management, Neurological Institute, Cleveland Clinic, Cleveland, OH 44106, USA.
Pharmaceuticals (Basel, Switzerland)
|May 27, 2023
概括
胰岛素样生长因子-1 (IGF-1) 和IGF-1受体 (IGF-1R) 抑制剂在治疗疼痛方面具有潜力,包括神经病痛. 需要进一步的研究来证实它们在缓解疼痛方面的有效性和安全性.
科学领域:
- 药理学和疼痛管理
- 神经科学和分子生物学
背景情况:
- 胰岛素样生长因子-1 (IGF-1) 在疼痛通路,包括 nociception 和神经再生中的作用是复杂的.
- 神经病变性疼痛和过敏症是具有有限有效治疗方法的重大临床挑战.
研究的目的:
- 审查IGF-1和IGF-1受体 (IGF-1R) 抑制剂在疼痛相关疾病中的作用.
- 评估IGF-1相关药物的治疗疼痛的有效性.
- 为了调查IGF-1在 nociception,神经再生和神经病痛发展中的参与.
主要方法:
- 在PUBMED/MEDLINE,Scopus和Cochrane图书馆进行系统的文献搜索 (截至2022年11月).
- 选了545篇文章,其中18篇根据摘要被选中,10篇在全文审查后被收录.
- 临床证据的分级和包括在内的人类研究的建议的含义.
主要成果:
- IGF-1 可能促进过敏症的解决,预防化疗诱导的神经病变,逆转神经元过活,并提高可感知值.
- 在动物模型中,IGF-1R抑制剂可缓解坐骨神经损伤,骨癌疼痛和子宫内膜异位症诱导的超痛.
- 人类研究显示出混合的结果:一个报告说,用IGF-1R抑制剂改善了与甲状腺相关的眼病,而两个发现IGF-1治疗没有益处.
结论:
- IGF-1和IGF-1R抑制剂为疼痛管理提供了潜在的治疗途径.
- 进一步的研究是必不可少的,以阐明这些药物的完全有效性和潜在的副作用在疼痛条件.
- IGF-1和IGF-1R抑制剂的临床实用性需要更强大的研究.
相关概念视频
Glucagon-like Receptor Agonists
372
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
372
Opioid Analgesics: Synthetic and Semisynthetic Opioids
351
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
351
Analgesia and Pain Management
673
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
673
Drugs for Treatment of Diarrhea-Predominant IBS
223
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
223
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
178
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
178
Drugs for Treatment of Constipation-Predominant IBS
236
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
236

